Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol

Background: Metastatic renal cell carcinoma (mRCC) is notably resistant to chemotherapy and radiotherapy. However, tyrosine kinase inhibitors (TKIs) and checkpoint immunotherapy have significantly improved outcomes. Still, about 20% of patients experience disease progression as their best response t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jakob N. Henriksen, Charlotte U. Andersen, Frede Donskov, Elke Hoffmann-Lücke, Eva Greibe, Niels Fristrup
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Medical Journals Sweden 2025-06-01
Edice:	Acta Oncologica
Témata:	Metastatic renal cell carcinoma tyrosine kinase inhibitors therapeutic drug monitoring personalized medicine toxicity management
On-line přístup:	https://medicaljournalssweden.se/actaoncologica/article/view/43693
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!